StockNews.AI
VCEL
StockNews.AI
117 days

Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025

1. Vericel will report Q1 2025 results on May 8, 2025. 2. Management will host a conference call at 8:30 a.m. ET. 3. Vericel specializes in advanced therapies for sports medicine and burn care. 4. Key products include MACI, Epicel, and the licensed NexoBrid. 5. Investors can access the conference via the Investor Relations website.

Earnings
-0.75%Current Return
VS
+2.8%S&P 500
$40.0504/24 08:36 AM EDTEvent Start
$39.7504/25 03:05 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

The article announces upcoming earnings but lacks new operational insights. Historically, earnings reports can swing stock prices but depend on financial performance context.

How important is it?

Earnings announcements are crucial for stock valuation, affecting investor sentiment significantly. The lack of new product or market updates may temper investor enthusiasm.

Why Short Term?

Earnings release affects short-term sentiment, as markets react promptly post-announcement. No long-term shifts indicated yet.

Related Companies

MediWound Ltd. (MDWD)Zynex, Inc. (ZYXI)Sientra, Inc. (SIEN)
April 24, 2025 08:30 ET  | Source: Vericel Corporation CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2025 financial results on Thursday, May 8, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time to register and download the required audio software, if necessary. Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website.  To participate by telephone, please dial (800) 715-9871 or (646) 307-1963 if connecting from outside the U.S. When connected, please reference Vericel Corporation first-quarter 2025 earnings call to the operator. A replay of the webcast will be available on the Vericel website until May 8, 2026. About Vericel Corporation Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com. Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2025 Vericel Corporation. All rights reserved. Investor Contact: Eric Burnsir@vcel.com+1 (734) 418-4411

Related News